Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2018 2
2019 4
2020 3
2021 5
2022 7
2023 4
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.
Provenzano L, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, Rizzo G, Pedersini R, Sirico M, La Verde N, Gennari A, Zambelli A, Toss A, Piras M, Giordano M, Tagliaferri B, Generali D, Sartori D, Miliziano D, Menichetti A, Ligorio F, Zurlo C, Griguolo G, Berton Giachetti PP, Faso V, Corti C, Chiappe E, Scagnoli S, Pisegna S, Capasso C, De Angelis C, Arpino G, Criscitiello C, Guarneri V, Pruneri G, Mariani L, Vernieri C; PALMARES-2 Study Group. Provenzano L, et al. Ann Oncol. 2025 Jul;36(7):762-774. doi: 10.1016/j.annonc.2025.03.023. Epub 2025 Apr 8. Ann Oncol. 2025. PMID: 40204155 Free article.
An overview of immune checkpoint inhibitors in breast cancer.
Miglietta F, Cona MS, Dieci MV, Guarneri V, La Verde N. Miglietta F, et al. Among authors: cona ms. Explor Target Antitumor Ther. 2020;1(6):452-472. doi: 10.37349/etat.2020.00029. Epub 2020 Dec 28. Explor Target Antitumor Ther. 2020. PMID: 36046385 Free PMC article. Review.
Rising Concern About the Carcinogenetic Role of Micro-Nanoplastics.
Ruggieri L, Amato O, Marrazzo C, Nebuloni M, Dalu D, Cona MS, Gambaro A, Rulli E, La Verde N. Ruggieri L, et al. Among authors: cona ms. Int J Mol Sci. 2024 Dec 30;26(1):215. doi: 10.3390/ijms26010215. Int J Mol Sci. 2024. PMID: 39796071 Free PMC article. Review.
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives.
Vernieri C, Milano M, Brambilla M, Mennitto A, Maggi C, Cona MS, Prisciandaro M, Fabbroni C, Celio L, Mariani G, Bianchi GV, Capri G, de Braud F. Vernieri C, et al. Among authors: cona ms. Crit Rev Oncol Hematol. 2019 Jul;139:53-66. doi: 10.1016/j.critrevonc.2019.05.001. Epub 2019 May 3. Crit Rev Oncol Hematol. 2019. PMID: 31112882 Review.
Antibody response to three-dose anti-SARS-CoV-2 mRNA-vaccination in treated solid cancer patients.
Dalu D, Tarkowski M, Ruggieri L, Cona MS, Gabrieli A, De Francesco D, Fasola C, Ferrario S, Gambaro A, Masedu E, Parma G, Rulli E, De Stradis C, Mavilio D, Calcaterra F, Manoni F, Riva A, La Verde N. Dalu D, et al. Among authors: cona ms. Int J Cancer. 2024 Apr 15;154(8):1371-1376. doi: 10.1002/ijc.34817. Epub 2023 Dec 15. Int J Cancer. 2024. PMID: 38100252 Free article.
26 results